Status:
RECRUITING
99mTc-MIP-1404 SPECT/CT in Primary Staging of Prostate Cancer
Lead Sponsor:
Turku University Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
Prostate cancer (PCa) is currently the most common cancer in men in Finland (www.cancerregistry.fi). Although prognosis is very good in majority of men, it is noteworthy that still up to 20% of PCa ca...
Eligibility Criteria
Inclusion
- Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol
- Subjects must be male, aged 18 years or above at Baseline
- Histopathologically confirmed high risk (Gleason ≥4+4, PSA ≥20 and/ or cT≥3a) acinar or ductal adenocarcinoma of prostate
Exclusion
- Allergy/sensitivity to study medications or their ingredients
- Subjects unable to provide written informed consent
- Subjects who have any other significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk by participation in the study, or may influence the result of the study.
- Subjects who have a history of drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements.
- Subjects who have androgen deprivation therapy initiated before enrolment
- Subjects who have claustrophobia
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
320 Patients enrolled
Trial Details
Trial ID
NCT06219746
Start Date
June 1 2022
End Date
December 31 2026
Last Update
January 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Turku, Hospital Distric of Southwest Finland
Turku, Southwest Finland, Finland, 20521